NCT04259658 (CAEP-B) is a Phase 2 clinical trial of Calcium electroporation in Cancer, sponsored by Zealand University Hospital.

Who is sponsoring NCT04259658?

NCT04259658 is sponsored by Zealand University Hospital.

What drugs are being tested in NCT04259658?

Interventions in NCT04259658: Calcium electroporation.

Is NCT04259658 still recruiting?

NCT04259658 is currently completed. Last updated 3 October 2023.

Last reviewed 2023-10-03 · How we verify

NCT04259658: CAEP-B

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Histopathologic Effect of Calcium Electroporation on Cancer in the Skin

Completed Phase 2 Last updated 3 October 2023

What this trial tests

Phase 2 trial testing Calcium electroporation in Cancer in 17 participants. Completed in 27 July 2023.

Timeline

20 April 2020

Primary endpoint
19 October 2022

27 July 2023

Quick facts

Lead sponsor	Zealand University Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	17
Start date	20 April 2020
Primary completion	19 October 2022
Estimated completion	27 July 2023
Sites	1 location across Denmark

Drugs / interventions tested

Calcium electroporation — full drug profile →

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

Zealand University Hospital

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this phase II study we investigate the effect of calcium electroporation on cancer in the skin investigated by histopathology.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The Impact of Calcium Overload on Cellular Processes: Exploring Calcicoptosis and Its Therapeutic Potential in Cancer.
Gielecińska A, Kciuk M, Kontek R. · · 2024 · cited 23× · PMID 39769488 · DOI 10.3390/ijms252413727
Deciphering the Role of Ca<sup>2+</sup> Signalling in Cancer Metastasis: From the Bench to the Bedside.
Alharbi A, Zhang Y, Parrington J. · · 2021 · cited 17× · PMID 33430230 · DOI 10.3390/cancers13020179
In Vitro Study of Calcium Microsecond Electroporation of Prostate Adenocarcinoma Cells.
Kiełbik A, Szlasa W, Michel O, Szewczyk A, et al · · 2020 · cited 16× · PMID 33227916 · DOI 10.3390/molecules25225406
Electroporation and Electrochemotherapy in Gynecological and Breast Cancer Treatment.
Łapińska Z, Szwedowicz U, Choromańska A, Saczko J. · · 2022 · cited 11× · PMID 35458673 · DOI 10.3390/molecules27082476
Immune cell populations in the tumour environment following calcium electropora-tion for cutaneous metastasis: a histopathological study.
Vissing M, Sinius Pouplier S, Munch Larsen L, Krog Frandsen S, et al · · 2024 · cited 2× · PMID 38804839 · DOI 10.2340/1651-226x.2024.19462

Verify or expand the search:

Other trials of Calcium electroporation

Trials testing the same drug.

NCT05609656 — Electroporation and Immunotherapy in Metastatic Colorectal Cancer · Phase 2 · terminated
NCT04605419 — Calcium Electroporation in Patients With Cell Changes in the Esophagus · Phase 1 · unknown
NCT04225767 — Calcium Electroporation as a Treatment for Cutaneous and Subcutaneous Malignant Tumours · Phase 2 · unknown
NCT03694080 — Calcium Electroporation for Early Colorectal Cancer · Phase 1 · unknown
NCT03542214 — Calcium Electroporation for the Treatment of Colorectal Cancer · Phase 1 · completed

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Zealand University Hospital trials

Trials by the same sponsor.

NCT07373561 — Post-Intensive Care Syndrome and Associated Symptom Burden Among Danish ICU Survivors · not yet recruiting
NCT07386080 — Carbergoline for Antipsychotic Induced Hyperprolactinemia. · Phase 4 · not yet recruiting
NCT07482150 — The Connect Trial: Connecting Hospital Patients to Alcohol Care · NA · not yet recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07365527 — Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04259658 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zealand University Hospital
Last refreshed: 3 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04259658.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing